SGCB and left ventricular hypertrophy: Chronic in vivo treatment with sGC ligands such as BAY 58-2667 (also known as cinaciguat) or BAY 41-2272 can limit hypertension-driven left ventricular hypertrophy in experimental models, at least using relatively high dosing strategies [16]–[20].